GeneDx Holdings Corp. (NASDAQ:WGS) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 106.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 107,891 shares of the company's stock after acquiring an additional 55,730 shares during the period. JPMorgan Chase & Co. owned about 0.39% of GeneDx worth $8,293,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. MCF Advisors LLC grew its position in shares of GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after purchasing an additional 182 shares during the period. Global Retirement Partners LLC purchased a new stake in GeneDx in the 4th quarter valued at about $28,000. Rhumbline Advisers increased its stake in shares of GeneDx by 5.5% during the 4th quarter. Rhumbline Advisers now owns 19,750 shares of the company's stock valued at $1,518,000 after acquiring an additional 1,021 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of GeneDx by 10.6% during the 4th quarter. Principal Financial Group Inc. now owns 15,751 shares of the company's stock worth $1,211,000 after acquiring an additional 1,511 shares during the period. Finally, Palumbo Wealth Management LLC boosted its position in shares of GeneDx by 22.8% in the fourth quarter. Palumbo Wealth Management LLC now owns 8,303 shares of the company's stock worth $638,000 after acquiring an additional 1,542 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other GeneDx news, CFO Kevin Feeley sold 15,516 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $92.18, for a total value of $1,430,264.88. Following the transaction, the chief financial officer now owns 1,726 shares in the company, valued at $159,102.68. The trade was a 89.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Katherine Stueland sold 2,731 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $94.73, for a total value of $258,707.63. Following the sale, the chief executive officer now owns 7,752 shares of the company's stock, valued at $734,346.96. This represents a 26.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 138,780 shares of company stock worth $12,907,437 in the last 90 days. 27.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen lifted their target price on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, GeneDx has an average rating of "Moderate Buy" and a consensus target price of $72.33.

GeneDx Stock Down 2.9 %

Shares of NASDAQ:WGS traded down $2.81 during midday trading on Friday, hitting $95.47. 621,673 shares of the company's stock traded hands, compared to its average volume of 685,016. The firm's fifty day moving average price is $93.79 and its two-hundred day moving average price is $80.27. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a twelve month low of $9.60 and a twelve month high of $115.60. The company has a market cap of $2.68 billion, a PE ratio of -48.71 and a beta of 1.93.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. On average, equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.